These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36909561)

  • 1. Discovery of decreased ferroptosis in male colorectal cancer patients with KRAS mutations.
    Yan H; Talty R; Jain A; Cai Y; Zheng J; Shen X; Muca E; Paty PB; Bosenberg MW; Khan SA; Johnson CH
    bioRxiv; 2023 Mar; ():. PubMed ID: 36909561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of decreased ferroptosis in male colorectal cancer patients with KRAS mutations.
    Yan H; Talty R; Jain A; Cai Y; Zheng J; Shen X; Muca E; Paty PB; Bosenberg MW; Khan SA; Johnson CH
    Redox Biol; 2023 Jun; 62():102699. PubMed ID: 37086630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A machine learning and drug repurposing approach to target ferroptosis in colorectal cancer stratified by sex and KRAS.
    Yan H; Shen X; Yao Y; Khan SA; Ma S; Johnson CH
    bioRxiv; 2024 Jun; ():. PubMed ID: 38979294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
    Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
    Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
    [No Abstract]   [Full Text] [Related]  

  • 5. Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer.
    Yang J; Mo J; Dai J; Ye C; Cen W; Zheng X; Jiang L; Ye L
    Cell Death Dis; 2021 Nov; 12(11):1079. PubMed ID: 34775496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
    Wong CC; Qian Y; Li X; Xu J; Kang W; Tong JH; To KF; Jin Y; Li W; Chen H; Go MY; Wu JL; Cheng KW; Ng SS; Sung JJ; Cai Z; Yu J
    Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic and antitumor roles of key genes of ferroptosis in liver hepatocellular cancer and stomach adenocarcinoma.
    Pei W; Jiang M; Liu H; Song J; Hu J
    Cancer Biomark; 2024; 39(4):335-347. PubMed ID: 38393890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of BIK as an unfavorable prognostic marker and novel therapeutic target in microsatellite stable colorectal cancer harboring KRAS mutations.
    Liu P; Jiao F; Zhang Z; Zhao F; Cai J; Chen S; Fu T; Li M
    Am J Cancer Res; 2022; 12(11):5300-5314. PubMed ID: 36504908
    [No Abstract]   [Full Text] [Related]  

  • 9. Osthole inhibits malignant phenotypes and induces ferroptosis in KRAS-mutant colorectal cancer cells via suppressing AMPK/Akt signaling.
    Zhou X; Kang J; Zhang L; Cheng Y
    Cancer Chemother Pharmacol; 2023 Aug; 92(2):119-134. PubMed ID: 37318525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer.
    Nagasaka T; Koi M; Kloor M; Gebert J; Vilkin A; Nishida N; Shin SK; Sasamoto H; Tanaka N; Matsubara N; Boland CR; Goel A
    Gastroenterology; 2008 Jun; 134(7):1950-60, 1960.e1. PubMed ID: 18435933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erianin inhibits the growth and metastasis through autophagy-dependent ferroptosis in KRAS
    Miao Q; Deng WQ; Lyu WY; Sun ZT; Fan SR; Qi M; Qiu SH; Zhu YR; Lin JP; Chen MF; Deng LJ
    Free Radic Biol Med; 2023 Aug; 204():301-312. PubMed ID: 37217090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ferroptosis-Mediated Cell Death Induced by NCX4040, The Non-Steroidal Nitric Oxide Donor, in Human Colorectal Cancer Cells: Implications in Therapy.
    Sinha BK; Bortner CD; Jarmusch AK; Tokar EJ; Murphy C; Wu X; Winter H; Cannon RE
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
    Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
    Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective PI3Kδ inhibitor TYM-3-98 suppresses AKT/mTOR/SREBP1-mediated lipogenesis and promotes ferroptosis in KRAS-mutant colorectal cancer.
    Zheng YN; Lou SY; Lu J; Zheng FL; Tang YM; Zhang EJ; Cui SL; Zhao HJ
    Cell Death Dis; 2024 Jul; 15(7):474. PubMed ID: 38956060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship of KRAS expression with KRAS status, prognosis, and tumor-infiltrated T lymphocytes in colorectal cancer.
    Zhou Y; Zeng Z; Li Z; Ruan L; Xie H; Ye F; Huang L; Liu H; Kang L
    Therap Adv Gastroenterol; 2024; 17():17562848241249387. PubMed ID: 38757097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asparagine synthetase and G-protein coupled estrogen receptor are critical responders to nutrient supply in KRAS mutant colorectal cancer.
    Lu L; Zhang Q; Aladelokun O; Berardi D; Shen X; Marin A; Garcia-Milian R; Roper J; Khan SA; Johnson CH
    Int J Cancer; 2024 Jul; ():. PubMed ID: 39039782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RSL3 Drives Ferroptosis Through GPX4 Inactivation and ROS Production in Colorectal Cancer.
    Sui X; Zhang R; Liu S; Duan T; Zhai L; Zhang M; Han X; Xiang Y; Huang X; Lin H; Xie T
    Front Pharmacol; 2018; 9():1371. PubMed ID: 30524291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53-armed oncolytic adenovirus induces autophagy and apoptosis in KRAS and BRAF-mutant colorectal cancer cells.
    Tamura S; Tazawa H; Hori N; Li Y; Yamada M; Kikuchi S; Kuroda S; Urata Y; Kagawa S; Fujiwara T
    PLoS One; 2023; 18(11):e0294491. PubMed ID: 37972012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
    Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
    Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.